AI Biotech Firm BioMap Secures Strategic Investment from Hong Kong Investment Corporation, Eyes Hong Kong IPO

On June 24, HKIC, known as the "Hong Kong version of Temasek"（HKIC）Announced the second strategic partner, BioMap, co-founded by Baidu founder Robin Li and Baidu Ventures President Liu Wei, signing a strategic cooperation agreement.

HKIC will provide comprehensive resource matching and support for BioMap's subsequent development in Hong Kong, promoting Hong Kong's development into an international bio-computing hub. In response to the strategic cooperation with HKIC, BioMap hosted the first "International Bio-Computing Innovation Summit" and signed a strategic cooperation agreement during the summit, marking the beginning of deep collaboration between the two parties, with expectations.Helping Hong Kong Build a Bio-computing Ecosystem。

Mr. Paul Chan, Financial Secretary of the Hong Kong Special Administrative Region Government, witnessed the signing ceremony and delivered a speech. Ms. Karen Chan, CEO of HKIC, and Mr. Wei Liu, Co-founder and CEO of BioMap, signed on behalf of their respective parties.

▲ Ms. Chan Ka-kei, CEO of Hong Kong Investment Corporation (left), and Mr. Liu Wei, Co-founder and CEO of BioMap (right), sign a strategic cooperation agreement, witnessed by Mr. Paul Chan Mo-po, Financial Secretary of the Hong Kong Special Administrative Region Government (center).

Hong Kong Financial Secretary Paul Chan said, "The integration of artificial intelligence and life sciences is opening new frontiers in biocomputing. Hong Kong has a solid foundation in both areas and should strive to accelerate the development of biocomputing to seize the 'first-mover advantage'." He pointed out that Hong Kong's thriving innovation and technology ecosystem, advancements in AI infrastructure, convergence of domestic and international data, as well as its advantages as an international financial center, provide a strong foundation for the development of biocomputing.

HKIC CEO Ms. Chen Jiaqi stated that HKIC will lead the new round of financing for BioMap, with the investment amount undisclosed.Chen Jiaqi mentioned that the strategic cooperation between the two parties has four key points, including BioMap prioritizing Hong Kong as its IPO listing location.

Chen Jiaqi pointed out that BioMap has currently established the large model "XTrimo," which has over 100 billion parameters, described as the largest of its kind. It has reached the cutting-edge level in fields such as protein structure prediction, antibody sequence generation, and cell characterization, enabling scientists to more accurately simulate biological characteristics from proteins to system levels, facilitating breakthroughs in medical research.

Notably, another AI pharmaceutical company, QuantumPharm, has already gone public through an IPO on the Hong Kong stock market this month, taking the lead in the AI pharmaceutical field. There are nearly a hundred such companies in China.AI pharmaceutical companies may be "poised for action", see detailsChina's First AI Pharmaceutical Stock Successfully IPOsAn Article.

BioMap is a life science AI large model company with disruptive technology, founded by Robin Li and Liu Wei in 2020. The company is committed to combining cutting-edge AI and biotechnology, and has built the xTrimo platform, a foundational large model in life sciences centered on protein language, with hundreds of billions of parameters, modeling biological evolution and decoding the laws of life, bringing generative capabilities to the frontier discovery problems of the life science industry.Achieve a series of breakthrough results in innovative drug design, target discovery, de novo design of proteases, green technology, industrial innovation, and consumption upgrading, thereby promoting human health and sustainable social development.。

HKIC, established in 2022, currently manages four funds under the Hong Kong government: the "Hong Kong Growth Portfolio," "Greater Bay Area Investment Fund," "Strategic Technology Fund," and "Co-Investment Fund."Initial scale totaling 62 billion yuan, with the aim of promoting Hong Kong's strategic industries and innovation development.